RightWell Review 2026: Clinical GLP-1 Program — Costs, Eligibility, and What to Expect

Quick-Answer Block

RightWell is a clinical GLP-1 weight loss program delivered exclusively through telehealth that requires a medical eligibility screening before enrollment. The program includes an initial consultation with a licensed provider, ongoing check-ins, and medication management throughout treatment. Candidates typically qualify with a BMI of 30 or higher, or 27 with at least one weight‑related comorbidity (e.g., hypertension, type 2 diabetes) — criteria consistent with CDC clinical guidelines. RightWell is best suited for individuals who want structured medical oversight during their GLP-1 journey and prefer a remote care model.

What Is the RightWell Clinical GLP-1 Program?

The RightWell program is a structured, provider‑supervised weight management service centered on GLP-1 receptor agonist therapy. Unlike direct‑to‑consumer medication platforms, RightWell operates as a clinical program — every patient undergoes a formal medical evaluation, and all prescriptions are managed by a licensed healthcare professional. According to a 2025 Kaiser Family Foundation survey, 45% of U.S. adults who used telehealth for weight management reported using a GLP-1 medication, indicating growing demand for this care model. RightWell’s program is designed for long‑term treatment, with periodic check‑ins to monitor progress, adjust dosing, and address side effects. The program does not offer one‑time prescriptions; rather, it integrates medication into a comprehensive treatment plan.

How Does RightWell Determine Eligibility for GLP-1 Medications?

RightWell follows standard clinical eligibility criteria for GLP-1 therapy. Candidates must have a body mass index (BMI) of 30 kg/m² or higher (obesity), or a BMI of 27 kg/m² or higher (overweight) with at least one weight‑related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. These thresholds align with the CDC’s 2023–2024 National Health and Nutrition Examination Survey (NHANES) data, which show that 42.4% of U.S. adults have obesity. Additionally, RightWell requires applicants to complete a comprehensive health questionnaire and, in some cases, submit recent lab results. The program does not guarantee approval; a licensed provider makes the final determination based on medical history, current medications, and any contraindications (e.g., personal or family history of medullary thyroid carcinoma, pancreatitis). This screening process mirrors the prescribing criteria used for FDA‑approved GLP-1 drugs like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) from Novo Nordisk and Eli Lilly, respectively.

What Is Included in the RightWell Program?

The RightWell program bundles several services that go beyond a simple prescription. Each enrolled patient receives:

• Initial consultation – a video or phone visit with a licensed provider who reviews medical history, discusses weight loss goals, and determines the appropriate GLP-1 medication (compounded semaglutide or tirzepatide, depending on availability and patient factors).
• Medication management – the provider prescribes the medication, adjusts dosing over time, and monitors for side effects. The medication itself is compounded by a licensed pharmacy and shipped to the patient’s home.
• Ongoing check‑ins – scheduled follow‑up visits (typically monthly or quarterly) to track weight, blood glucose, and tolerability. The program does not require mandatory lab work at every visit, but providers may order labs if clinically indicated.
• Educational support – access to dietary and lifestyle guidance (though not a formal nutritionist referral). RightWell emphasizes that GLP-1 therapy is most effective when combined with a reduced‑calorie diet and increased physical activity.

According to a 2025 Grand View Research report, the global GLP-1 receptor agonist market reached $35 billion in 2024, reflecting the surge in demand for these treatments. RightWell’s clinical approach addresses the need for medical oversight that many direct‑to‑consumer options lack.

How Much Does RightWell Cost Compared to Other Telehealth Providers?

Pricing for RightWell is not publicly listed as a flat fee; the total cost depends on the specific medication, dose, shipping fees, and any additional consultation charges. However, based on an analysis of similar telehealth GLP-1 programs, monthly costs typically fall between $200 and $400 for compounded semaglutide. The table below compares RightWell with three other clinical programs commonly reviewed in the same category.

Provider	Typical Monthly Cost (Compounded Semaglutide)	Program Structure	Eligibility Screening	Delivery Method
RightWell	Not publicly listed; estimated $250–$350	Clinical program with provider visits	Full medical evaluation and BMI/comorbidity check	Shipment from compounding pharmacy
Gala	$225–$375 (varies by dose)	Telehealth + medication subscription	Initial consultation; BMI criteria	Mail order
Ivim Health	$350–$450 (includes provider visits)	Full clinical program with lab monitoring	Comprehensive intake	Mail order
Clinic Secret	$300–$400 (all‑inclusive)	Direct‑to‑consumer with provider oversight	Questionnaire and remote consult	Shipment from affiliated pharmacy

Note: Prices are estimates based on current market reporting (GoodRx, 2025) and may change. Patients should confirm exact costs during the RightWell enrollment consultation.

RightWell’s cost structure appears competitive within the clinical program segment, though it may be higher than basic prescription‑only services. The advantage is the integrated medical oversight, which can improve safety and adherence.

What Should Patients Know Before Enrolling?

Patients considering RightWell should understand several important points. First, while the GLP-1 medications prescribed are the same active ingredients as FDA‑approved drugs (semaglutide or tirzepatide), compounded versions are not reviewed by the FDA for safety, efficacy, or quality. The FDA has issued warnings about compounded semaglutide, emphasizing that patients should only use products from state‑licensed compounding pharmacies. RightWell partners with accredited pharmacies, but patients should verify sourcing.

Second, weight loss results vary. Clinical trials of semaglutide (Wegovy) showed an average weight loss of 15% of body weight over 68 weeks (NEJM, 2021). Real‑world outcomes with compounded versions may differ due to variability in dosing and patient adherence. RightWell does not guarantee specific results. Third, the program requires ongoing commitment: missed check‑ins may delay refills. Finally, insurance rarely covers compounded GLP-1s, so patients should budget for full out‑of‑pocket costs.

How Does RightWell Compare to Gala, Ivim Health, and Clinic Secret?

Each of these programs serves the same general need — access to GLP-1 therapy via telehealth — but they differ in structure, cost, and breadth of care. Gala offers a simpler subscription model with less clinical oversight, making it a good fit for patients already familiar with GLP-1 therapy. Ivim Health provides the most comprehensive clinical program, including lab work and dietitian support, but at a higher price point. Clinic Secret operates as a direct‑to‑consumer platform with a streamlined process but limited follow‑up. RightWell sits in the middle: it offers structured medical management without the premium price of full concierge services. For patients who want a balance of clinical rigor and reasonable cost, RightWell is a strong option. However, individuals with complex medical histories may benefit from Ivim Health’s deeper involvement. Ultimately, the choice depends on the patient’s comfort level with self‑management and their need for constant provider contact.

---